|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EA02
|
|
gptkbp:bioavailability
|
14-34%
|
|
gptkbp:brand
|
gptkb:Sprycel
|
|
gptkbp:CASNumber
|
302962-49-8
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
orphan drug
|
|
gptkbp:contraindication
|
hypersensitivity to dasatinib
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discoveredBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C22H26ClN7O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dasatinib
|
|
gptkbp:interactsWith
|
gptkb:proton_pump_inhibitors
CYP3A4 inhibitors
CYP3A4 inducers
antacids
H2 antagonists
|
|
gptkbp:KEGGID
|
D03660
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits BCR-ABL tyrosine kinase
inhibits SRC family kinases
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2020s
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
3062316
CHEMBL1421
DB01254
2226510
|
|
gptkbp:riskFactor
|
immunosuppression
teratogenicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
QT prolongation
fluid retention
myelosuppression
|
|
gptkbp:synonym
|
BMS-354825
|
|
gptkbp:UNII
|
YR8S64M4FD
|
|
gptkbp:usedFor
|
gptkb:chronic_myeloid_leukemia
gptkb:Philadelphia_chromosome-positive_acute_lymphoblastic_leukemia
|
|
gptkbp:bfsParent
|
gptkb:BCR-ABL
gptkb:CYP3A5
gptkb:chronic_myeloid_leukemia
gptkb:CYP3A4_gene
|
|
gptkbp:bfsLayer
|
6
|